Patient Derived Xenograft / PDX Models

Global Patient Derived Xenograft / PDX Models Market to Reach US$1.0 Billion by 2030

The global market for Patient Derived Xenograft / PDX Models estimated at US$467.5 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 14.3% over the analysis period 2024-2030. Mice PDX Models, one of the segments analyzed in the report, is expected to record a 14.9% CAGR and reach US$799.3 Million by the end of the analysis period. Growth in the Rat PDX Models segment is estimated at 12.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$231.3 Million While China is Forecast to Grow at 15.5% CAGR

The Patient Derived Xenograft / PDX Models market in the U.S. is estimated at US$231.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$88.3 Million by the year 2030 trailing a CAGR of 15.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.7% and 13.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.6% CAGR.

Global Patient-Derived Xenograft (PDX) Models Market – Key Trends & Drivers Summarized

How Are PDX Models Revolutionizing Cancer Research and Drug Development?

Patient-derived xenograft (PDX) models have emerged as a powerful tool in cancer research and drug development, offering more accurate representations of human tumor biology compared to traditional cell lines and animal models. PDX models are created by implanting human tumor tissues directly into immunodeficient mice, allowing the tumor to grow and be studied in a living organism. This process preserves the genetic and histological characteristics of the original tumor, including its microenvironment and heterogeneity, which are critical for understanding cancer’s behavior and treatment responses. PDX models provide a more realistic platform for testing the efficacy of new cancer therapies, allowing researchers to observe how tumors evolve and react to different drugs in vivo. These models have become essential for precision medicine, enabling the identification of patient-specific treatments and offering hope for improved clinical outcomes. As personalized cancer therapies gain traction, the demand for PDX models continues to rise, significantly impacting oncology research.

Why Is the Pharmaceutical Industry Investing Heavily in PDX Models?

The pharmaceutical and biotechnology industries are increasingly adopting patient-derived xenograft (PDX) models in preclinical studies to enhance the success rate of clinical trials. Traditional in vitro and animal models often fail to accurately predict how a human tumor will respond to a treatment, contributing to the high failure rate of oncology drugs in clinical trials. PDX models, on the other hand, provide a more reliable means of evaluating drug efficacy and toxicity, thus improving the chances of clinical success. Pharmaceutical companies are leveraging PDX models to conduct more efficient drug screening, reduce time to market, and lower the costs associated with drug development. Furthermore, the integration of genomic and transcriptomic data from PDX models allows for the identification of biomarkers that can guide patient selection and stratification in clinical trials. This personalized approach enhances the precision of targeted therapies and immunotherapies, increasing the likelihood of successful treatment outcomes. As the need for more predictive preclinical models grows, the pharmaceutical industry`s investment in PDX technology is expected to accelerate.

How Are PDX Models Enhancing Personalized Medicine and Precision Oncology?

PDX models are playing a pivotal role in the advancement of personalized medicine and precision oncology. By maintaining the biological integrity of the original patient tumor, PDX models allow researchers to study tumor-specific drug responses and identify personalized treatment options. This is particularly important in cancers where patient outcomes vary widely depending on genetic mutations and molecular markers. The use of PDX models in preclinical research enables scientists to tailor therapies to individual patients, increasing the likelihood of successful treatment. Additionally, PDX models are being used to develop combination therapies and evaluate resistance mechanisms, offering insights into how tumors may evolve during treatment and relapse. With the rising emphasis on developing therapies that are tailored to the unique genetic profiles of patients, PDX models are becoming indispensable tools for predicting treatment responses, guiding clinical decision-making, and advancing the field of precision oncology.

What Factors Are Driving Growth in the Patient-Derived Xenograft (PDX) Models Market?

The growth in the patient-derived xenograft (PDX) models market is driven by several factors that are reshaping cancer research and drug development. Technological advancements in genetic sequencing and molecular profiling have significantly enhanced the ability to create and analyze PDX models, making them more predictive and valuable in preclinical testing. The increasing focus on precision medicine and personalized cancer therapies is another major driver, as PDX models offer a more accurate and patient-specific platform for evaluating treatment responses. Pharmaceutical companies are adopting PDX models to improve the efficiency of drug development and reduce the high failure rates associated with traditional clinical trials. Furthermore, the rise in cancer incidence worldwide and the growing demand for novel, targeted therapies are fueling the need for advanced preclinical models like PDX. Additionally, collaborations between academic institutions, research organizations, and pharmaceutical companies are accelerating the development and commercialization of PDX platforms, further driving market growth. As the landscape of oncology research continues to evolve, the demand for PDX models is expected to expand, solidifying their role as a cornerstone of cancer research and drug development.

SCOPE OF STUDY:

The report analyzes the Patient Derived Xenograft / PDX Models market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Model Type (Mice PDX Models, Rat PDX Models); Tumor Type (Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Other Tumor Types); Application (Pre-Clinical Drug Development Application, Biomarker Analysis Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, CROs / CDMOs End-Use, Academic & Research Institutes End-Use)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Abnova Corporation
• Altogen Labs
• Aragen Life Sciences
• Biocytogen Pharmaceuticals Co., Ltd.
• Certis Oncology Solutions
• Champions Oncology, Inc.
• Charles River Laboratories
• Creative Animodel
• Crown Bioscience Inc.
• EPO Berlin-Buch GmbH
• InnoSer
• Inotiv, Inc.
• Oncodesign Services
• Shanghai Chempartner Co. Ltd.
• LIDE Shanghai Biotech, Ltd.
• The Jackson Laboratory
• Wuxi AppTec
• Xenopat
• Xentech

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.